Fibrillary Glomerulonephritis
- 4 November 2019
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Journal of the American Society of Nephrology
- Vol. 14 (12), 1741-1750
- https://doi.org/10.2215/cjn.03870319
Abstract
Background and objectives Fibrillary GN has been defined as an immune complex-mediated GN with amyloid-like fibrils larger than amyloid which are IgG positive and Congo red negative. With discovery of DNAJB9 as a highly sensitive and specific marker for fibrillary GN, the specificity of the morphologic criteria for establishing the diagnosis of fibrillary GN has come into question. Design, setting, participants, & measurements We sought to (1) determine anatomic characteristics that best define fibrillary GN and (2) identify clinical and pathologic features that predict outcomes. Results We retrospectively reviewed kidney biopsies from patients diagnosed with fibrillary GN or suspected fibrillary GN between 1997 and 2017 (n=266, 65% female, median age 61). Approximately 11% of kidney biopsies had one or more unusual feature including monotypic deposits, Congo red positivity, or unusual fibril diameter. Fibrillary GN as a possible monoclonal gammopathy of renal significance represented n=100), 53% of patients reached the combined primary outcome of ESKD or death, 18% had CKD, and 18% had partial remission. On multivariable analysis, male sex (adjusted hazard ratio [aHR], 3.82; 95% confidence interval [95% CI], 1.97 to 7.37) and eGFR were the most significant predictors of primary outcome (aHR of 8.02 if eGFR 2 [95% CI, 1.85 to 34.75]; aHR of 6.44 if eGFR 30 to 2 [95% CI, 1.38 to 29.99]). Immunosuppressive therapy with rituximab was significantly associated with stabilization of disease progression. Conclusions Detection of DNAJB9 is a useful diagnostic tool for diagnosing atypical forms of fibrillary GN. The outcomes for fibrillary GN are poor and progression to ESKD is influenced predominantly by the degree of kidney insufficiency at the time of diagnosis and male sex. Rituximab may help preserve kidney function for select patients with fibrillary GN. Podcast This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2019_11_04_CJN03870319.mp3Keywords
This publication has 36 references indexed in Scilit:
- Gender Differences in the Pathogenesis and Outcome of Lupus and of Lupus NephritisJournal of Immunology Research, 2012
- Fibrillary GlomerulonephritisClinical Journal of the American Society of Nephrology, 2011
- Prevalence of Monoclonal Gammopathy of Undetermined Significance: A Systematic ReviewMayo Clinic Proceedings, 2010
- Rituximab Treatment of Fibrillary GlomerulonephritisAmerican Journal of Kidney Diseases, 2008
- Variability and Risk Factors for Kidney Disease Progression and Death Following Attainment of Stage 4 CKD in a Referred CohortAmerican Journal of Kidney Diseases, 2008
- Fibrillary Glomerulonephritis and Immunotactoid GlomerulopathyJournal of the American Society of Nephrology, 2008
- Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsiesKidney International, 2004
- Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic featuresKidney International, 2003
- The impact of gender on the progression of chronic renal diseaseAmerican Journal of Kidney Diseases, 1995
- Fibrillary glomerulonephritis: An entity with unusual immunofluorescence featuresKidney International, 1987